Lankenau Institute for Medical Research

Seventy-five percent of pancreatic cancer patients die within the first 12 months of their diagnosis. In a collaborative project, George Prendergast, Ph.D., Professor, President & CEO at the Lankenau Institute for Medical Research (LIMR) and Iraimoudi Ayene, Ph.D., Associate Professor at LIMR, received a one-year $125,000 grant from the Elsa U. Pardee Foundation to conduct the research project entitled Novel Immunochemotherapy for Pancreatic Cancer Treatment. - July 28, 2010

Affecting more than 1.3 million people in the United States alone, rheumatoid arthritis (RA) is a debilitating disease that causes pain, swelling, and stiffness in the joints. Dr. Laura Mandik-Nayak, Assistant Professor at the Lankenau Institute for Medical Research (LIMR), received a five-year, $1,856,250... - July 21, 2010

CureDM, LLC, a biopharmaceutical company with collaborative ties to the Lankenau Institute for Medical Research (LIMR), announced that they have signed an agreement with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1... - April 16, 2010

Alzheimer’s disease (AD), which afflicts over 5.3 million people in the United States alone, is the most common of over 25 incurable protein misfolding diseases termed amyloidoses. In a paper published in The Journal of Biological Chemistry, Sharad P. Adekar, MD, Scientist at the Lankenau Institute for Medical Research (LIMR) and Scott Dessain, M.D., Ph.D. Associate Professor at LIMR, have discovered a potential new antibody therapy that can be used to treat individuals suffering with AD. - November 09, 2009

Immunome, Inc., President and CEO, Tim Pelura, Ph.D., will be presenting information about the company on Monday, November 9, 2009 at the Pharmaceutical Consulting Consortium, Inc. (PCCI) Meeting. The presentation will be also be available for viewing via webcast at www.rxpcci.com. Immunome is a start-up... - November 08, 2009

Dr. Janet Sawicki, Professor at the Lankenau Institute for Medical Research (LIMR), along with its collaborating institution, the Massachusetts Institute of Technology (MIT), published a paper in Cancer Research whose findings suggest a potential new therapy to treat advanced stage ovarian cancer. - August 01, 2009

Dr. Mindy George-Weinstein, Professor at the Lankenau Institute for Medical Research (LIMR), in collaboration with Dr. Sue Menko, Professor at Thomas Jefferson University, received a three-year grant in the amount of $264,410 from the March of Dimes to study the development of eye defects that may lead to cataracts, glaucoma, increased sensitivity to light, squinting or blindness in newborns. - June 13, 2009

The research group of Dr. James Michael Mullin, Professor at the Lankenau Institute for Medical Research (LIMR), is conducting a clinical trial for patients with Crohn’s Disease. Past work of Dr. Mullin’s group has shown that dietary restriction of the amino acid methionine can improve the junctional seals between epithelial cells. This holds the promise that dietary restriction of methionine may be able to improve intestinal linings of Crohn’s patients, thereby reducing their disease symptoms. - April 26, 2009

The Lankenau Institute for Medical Research (LIMR) and its collaborating institution, the Massachusetts Institute of Technology (MIT), announced on March 9, 2009, that LIMR has been selected by the National Cancer Institute (NCI) for a research collaboration to perform preclinical studies on novel therapeutic nanoparticles for treatment of solid tumors. The research will be conducted by the NCI’s Nanotechnology Characterization Laboratory (NCL). - March 11, 2009

Ovarian cancer is the fourth most common cancer in women and has the highest mortality rate for gynecologic cancers because it is often diagnosed at an advanced stage. New effective therapies for the treatment of advanced stage ovarian cancer are urgently needed. A paper published February 9, 2009,... - February 11, 2009

A team of researchers from CureDM, Inc, in collaboration with the Lankenau Institute for Medical Research (LIMR) reported a ground breaking discovery with the potential to reverse type 1 and type 2 diabetes. In a paper published in Endocrine Practice, the leading peer-reviewed journal for practicing... - February 05, 2009

The research group of Dr. James Michael Mullin, Professor at the Lankenau Institute for Medical Research (LIMR), recently co-authored two papers that describe how proton pump inhibitors (PPIs) have been shown to compromise upper gastrointestinal (GI) barrier function. These studies provide new information about an unexpected potentially harmful side effect of taking PPIs. - December 24, 2008

Many cancers are believed to be caused or accelerated by chronic inflammation, such as skin, lung, colon, and prostate cancers. Genes that connect inflammation and cancer are of great medical interest because they may offer tactics to prevent or treat these diseases. Today, a team of researchers at the... - October 26, 2008

A new paper published in PLoS One, an international, peer-reviewed, open access, online publication by the Public Library of Science, have revealed an additional mechanism to neutralize Botuliimum neurotoxins (BoNTs). BoNTs are a family of toxins that cause the disease botulism, but they can also be used as bioterror agents that cause paralysis when they poison the neurons that transmit the signals responsible for breathing and muscular movement. - August 22, 2008